drugset
drugset / Trial / NCT03697603

A Study of Brexpiprazole in Patients With Major Depressive Disorder

NCT03697603 ↗

Phase 2/3 Completed 740 enrolled Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder.

Timeline

Start
2018-07-30
Primary completion
2022-06-06
Completion
2022-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 1 mg Oral
Subject Brexpiprazole Small molecule 2 mg Oral

Indications

major depressive disorder